- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | bioAffinity Technologies stock hits 52-week low at $1.21 | 2 | Investing.com | ||
| BIOAFFINITY TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
| 14.11. | bioAffinity Technologies GAAP EPS of -$0.16 misses by $0.01, revenue of $2.35M misses by $0.19M | 3 | Seeking Alpha | ||
| 14.11. | bioAffinity Technologies-Aktie erreicht 52-Wochen-Tief bei 1,24 US-Dollar | 1 | Investing.com Deutsch | ||
| 14.11. | bioAffinity Technologies, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.11. | bioAffinity Technologies Reports $2.4 Million Revenue for Q3 2024 | 59 | Business Wire | SAN ANTONIO--(BUSINESS WIRE)--bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage... ► Artikel lesen | |
| 30.10. | bioAffinity secures Japanese patent for lung health test | 3 | Investing.com | ||
| 21.10. | WallachBeth Capital LLC: WallachBeth Capital Announces Closing of bioAffinity Technologies $2.6 Million Registered Direct Offering & Concurrent Private Placement | 67 | PR Newswire | JERSEY CITY, N.J., Oct. 21, 2024 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies... ► Artikel lesen | |
| 21.10. | bioAffinity Technologies, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 16.10. | bioAffinity VP contributes to new cytometry guidelines | 1 | Investing.com | ||
| 10.10. | BioAffinity Technologies names new CFO | 1 | MassDevice | ||
| 10.10. | bioAffinity Technologies names J. Michael Edwards as CFO | 1 | Seeking Alpha | ||
| 07.10. | bioAffinity Technologies erhält Zustimmung der Aktionäre für Optionsausübung | 1 | Investing.com Deutsch | ||
| 07.10. | bioAffinity Technologies secures shareholder nod for warrant exercise | 1 | Investing.com | ||
| 07.10. | bioAffinity Technologies, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.09. | bioAffinity Technologies announces secondary offering of 1.8M shares | 1 | Seeking Alpha | ||
| 11.09. | bioAffinity Technologies, Inc. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 26.08. | BioAffinity Technologies CFO resigns to take on similar role in energy industry | 1 | MassDevice | ||
| 23.08. | bioAffinity Technologies CFO Michael Dougherty to depart | 1 | Seeking Alpha | ||
| 23.08. | bioAffinity Technologies, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 15.08. | bioAffinity Technologies GAAP EPS of -$0.19, revenue of $2.4M | 1 | Seeking Alpha |
Seite:
1 2 Weiter >>
31 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 1,200 | +20,00 % | EQS-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Epigenomics AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Epigenomics AG: Vorabbekanntmachung über die... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,361 | -1,63 % | Defence Therapeutics Inc.: Defence Therapeutics Announces Securities for Debenture Financing | Vancouver, British Columbia--(Newsfile Corp. - November 14, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company... ► Artikel lesen | |
| GINKGO BIOWORKS | 6,900 | +9,52 % | Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Sees Significant Drop in Short Interest | ||
| RECURSION PHARMACEUTICALS | 5,695 | -1,04 % | Recursion Pharmaceuticals, Inc.: Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery | Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programsPlatform will... ► Artikel lesen | |
| BEAM THERAPEUTICS | 25,070 | +6,32 % | Beam Therapeutics Inc. (NASDAQ:BEAM) Sees Large Increase in Short Interest | ||
| ONCOLYTICS BIOTECH | 0,915 | 0,00 % | Oncolytics Biotech Inc. (NASDAQ:ONCY) Q3 2024 Earnings Call Transcript | ||
| ARCTURUS THERAPEUTICS | 16,920 | -0,88 % | Arcturus Therapeutics Holdings Inc.: Arcturus Therapeutics to Present at Jefferies London Healthcare Conference | Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities... ► Artikel lesen | |
| ASSERTIO | 0,936 | -1,47 % | Assertio Holdings-Direktorin Heather Mason kauft Aktien im Wert von 60.000 US-Dollar | ||
| SIGA TECHNOLOGIES | 6,500 | +3,83 % | SIGA Technologies - TPOXX chalks up another DoD contract win | SIGA Technologies announced another contract win with the US Department of Defense (DoD), which is for the procurement of c $9m in TPOXX. This is the third DoD contract win in roughly three years for... ► Artikel lesen | |
| ADMA BIOLOGICS | 21,160 | -0,63 % | ADMA BIOLOGICS, INC. - 8-K, Current Report | ||
| VIR BIOTECHNOLOGY | 7,120 | +2,37 % | Needham & Company LLC Reaffirms Buy Rating for Vir Biotechnology (NASDAQ:VIR) | ||
| VERVE THERAPEUTICS | 4,835 | +5,11 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on October 31, 2024... ► Artikel lesen | |
| TRAVERE THERAPEUTICS | 17,900 | +2,29 % | Kidney Disease Leader Travere Therapeutics Pulls Back To Key Level | ||
| ARVINAS | 25,850 | +2,82 % | Arvinas, Inc. (ARVN): This Small-Cap Stock Is Ready To Explode | ||
| BIO-PATH | 0,810 | +8,00 % | Bio-Path Holdings, Inc.: Bio-Path Holdings Reports Third Quarter 2024 Financial Results | Expands DNAbilize® Technology Beyond Oncology into Obesity Conference Call to be Held Today at 8:30 A.M. ET HOUSTON, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology... ► Artikel lesen |
BIOAFFINITY TECHNOLOGIES INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,005 (+0,40 %) liegt der Kurs bei 1,240 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOAFFINITY TECHNOLOGIES INC finden Sie auf Wallstreet Online.
